- Category
- Small (2023-24)
- Udyam number
- UDYAM-HP-11-0002235

About Dallas Drugs Private Limited
Data last updated:
Dallas Drugs Private Limited is a private limited company based in Chandigarh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 April 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U15400CH2012PTC033748. Its GSTIN is 02AABCF9584E2ZO (Himachal Pradesh). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹3 Cr. It was formerly known as Friska Foods Private Limited. It is led by directors Rajesh Gupta and Anil Kumar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at SCO No. 805 1st Floor (Half Portion At 1st Floor) N.A.C Manimajra, Chandigarh, India – 160002.
As per the financials filed for FY 2025, the company reported a revenue of ₹12.01 Cr, a growth of 138% compared to the previous year. For the same year it recorded a net profit of ₹19.62 Lakh (net margin 1.6%) and EBITDA of ₹2.69 Cr (EBITDA margin 22.4%). Revenue has grown at a compounded annual rate (CAGR) of 112% over five years.
The company has about 16 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Dallas Drugs. As per MCA filings, the company has open charges of ₹7.46 Cr on record.
Dallas Drugs Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0002235). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dallasdrugs.org.
Company details
Recognitions & Rankings of Dallas Drugs
Contact details
Dallas Drugs Private Limited's registered office is in Chandigarh, Chandigarh. Its website is dallasdrugs.org. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSCO No. 805 1st Floor (Half Portion At 1st Floor) N.A.C Manimajra, Chandigarh, India – 160002
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dallas Drugs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Dallas Drugs operates one associated brand: Dallas Drugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturing of pharmaceutical tablets and capsules for domestic and export markets in the healthcare sector. | dallasdrugs.org |
Business activity
The main business activity of Dallas Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Dallas Drugs Private Limited, buy the company report.
Financials of Dallas Drugs Private Limited
FY 2025 filings availableDallas Drugs Private Limited reported revenue of ₹12.01 Cr (up 138% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 112% over five years, including 138% growth in the latest year. EBITDA rose 20% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.69 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹19.62 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 22.4% | ||||
| Net Profit Margin | 1.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dallas Drugs Private Limited, buy the company report.
Board of directors of Dallas Drugs Private Limited
Dallas Drugs has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajesh Gupta Also directs: Rudraksha Entertainment LLP, Dauket Pharma Private Limited, Delantero Pharma Private Limited and 3 more | Director | 29 Sep 2018 | 8 Years 1 Months | Current |
| Anil Kumar | Director | 29 Sep 2018 | 8 Years 1 Months | Current |
Peer comparison
Dallas Drugs Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Hilsun Foods and Drugs Private Limited | ₹12.06 Cr (FY 2024) | 29.0% | Thane, Maharashtra, India | |||
| Ainesh Pharma Private Limited | ₹12.05 Cr (FY 2025) | -10.0% | Vijayawada, Andhra Pradesh, India | |||
| Ardor Drugs Private Limited | ₹12.04 Cr (FY 2025) | -33.0% | Surat, Gujarat, India | |||
| Dallas Drugs Private Limitedthis company | ₹12.01 Cr (FY 2025) | ₹19.62 Lakh | 1.6% | 138.0% | 16 | Chandigarh, India |
| T'walker's Pharmaceuticals Private Limited | ₹12 Cr (FY 2024) | 21.0% | Pune, Maharashtra, India | |||
| Samay Pharma India Private Limited | ₹11.93 Cr (FY 2025) | 2.0% | Delhi, India |
To see the full peer comparison of Dallas Drugs Private Limited, buy the company report.
Auditor
Dallas Drugs Private Limited is audited by Nerkar & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Nerkar & Co. | FY 2024 | 021335C |
Shareholding
The shareholding of Dallas Drugs Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dallas Drugs Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Apr 2019 | 100268414 | State Bank of India | ₹7.46 Cr | Open |
To see the full charge records of Dallas Drugs Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Dallas Drugs Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dallas Drugs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Dallas Drugs Private Limited has a workforce of 16 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 16 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 |
To see the full employee and EPFO history of Dallas Drugs Private Limited, buy the company report.
GST
Dallas Drugs has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AABCF9584E2ZO | Himachal Pradesh | Active | 10 Jan 2019 |
To see the full GST registrations and return filing status of Dallas Drugs Private Limited, buy the company report.
Recent activity
Dallas Drugs Private Limited has 4 board changes on record since 2018: 2 appointments and 2 cessations. The latest: Amrinder Singh Sidhu ceased to be Director on 26 Oct 2018.
Frequently asked questions
Dallas Drugs is an active private limited company based in Chandigarh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 April 2012 (14+ years old) and is registered under CIN U15400CH2012PTC033748.
Dallas Drugs has 2 current directors:
- Rajesh Gupta - Director
- Anil Kumar - Director
The latest financial statements of Dallas Drugs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Dallas Drugs is 02AABCF9584E2ZO, registered in Himachal Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Dallas Drugs is U15400CH2012PTC033748. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dallas Drugs was incorporated on 25 April 2012, making it 14+ years old. It is registered with the Registrar of Companies, Chandigarh.
The peers of Dallas Drugs by revenue are Hilsun Foods and Drugs Private Limited, Ainesh Pharma Private Limited, Ardor Drugs Private Limited, T'walker's Pharmaceuticals Private Limited, Samay Pharma India Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Amrinder Singh Sidhu ceased to be Director on 26 Oct 2018. Pukhraj Sidhu ceased to be Director on 02 Oct 2018. Anil Kumar was appointed as Director on 29 Sep 2018. Dallas Drugs has 4 board changes on record in total.
Yes, Dallas Drugs is registered as a small enterprise under Udyam registration (number: UDYAM-HP-11-0002235).
Dallas Drugs can be reached through the website dallasdrugs.org. Its registered office is in Chandigarh, India.
The registered office of Dallas Drugs is at SCO No. 805 1st Floor Half Portion At 1st Floor N.A.C Manimajra, Chandigarh, India – 160002.

